Brokerages Set Senti Biosciences, Inc. (NASDAQ:SNTI) PT at $9.00

Shares of Senti Biosciences, Inc. (NASDAQ:SNTI) have received an average rating of “Moderate Buy” from the five brokerages that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $9.00.

Several analysts have weighed in on the stock. Chardan Capital lifted their price objective on shares of Senti Biosciences from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Wall Street Zen upgraded shares of Senti Biosciences to a “sell” rating in a research report on Saturday, December 13th. Leerink Partners initiated coverage on Senti Biosciences in a research report on Friday, November 21st. They set an “outperform” rating and a $6.00 price target on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Senti Biosciences in a report on Thursday, January 22nd. Finally, HC Wainwright started coverage on Senti Biosciences in a report on Tuesday, October 14th. They set a “buy” rating and a $12.00 target price on the stock.

Hedge Funds Weigh In On Senti Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in SNTI. Armistice Capital LLC bought a new stake in shares of Senti Biosciences during the 2nd quarter worth approximately $1,883,000. Geode Capital Management LLC lifted its stake in Senti Biosciences by 395.6% during the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after purchasing an additional 117,588 shares during the last quarter. Finally, Citadel Advisors LLC acquired a new stake in shares of Senti Biosciences in the 3rd quarter valued at $117,000. 25.70% of the stock is currently owned by institutional investors and hedge funds.

Senti Biosciences Trading Up 13.1%

Senti Biosciences stock opened at $0.93 on Wednesday. The company has a market capitalization of $24.46 million, a price-to-earnings ratio of -0.28 and a beta of 2.13. Senti Biosciences has a 12 month low of $0.80 and a 12 month high of $5.10. The stock’s 50 day moving average is $1.24 and its 200-day moving average is $1.55.

Senti Biosciences (NASDAQ:SNTI) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.10). As a group, equities research analysts predict that Senti Biosciences will post -14.54 earnings per share for the current fiscal year.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.